The lung microbiome in end-stage Lymphangioleiomyomatosis

Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease with mortality driven primarily by respiratory failure. Patients with LAM frequently have respiratory infections, suggestive of a dysregulated microbiome. Here we demonstrate that end-stage LAM patients have a distinct microbiome si...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Julie, Pacheco-Rodriguez, Gustavo, Begley, Lesa, Huang, Yvonne J., Poli, Sergio, Perrella, Mark A., Rosas, Ivan O., Moss, Joel, El-Chemaly, Souheil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549264/
https://www.ncbi.nlm.nih.gov/pubmed/34702264
http://dx.doi.org/10.1186/s12931-021-01873-y
_version_ 1784590748644016128
author Ng, Julie
Pacheco-Rodriguez, Gustavo
Begley, Lesa
Huang, Yvonne J.
Poli, Sergio
Perrella, Mark A.
Rosas, Ivan O.
Moss, Joel
El-Chemaly, Souheil
author_facet Ng, Julie
Pacheco-Rodriguez, Gustavo
Begley, Lesa
Huang, Yvonne J.
Poli, Sergio
Perrella, Mark A.
Rosas, Ivan O.
Moss, Joel
El-Chemaly, Souheil
author_sort Ng, Julie
collection PubMed
description Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease with mortality driven primarily by respiratory failure. Patients with LAM frequently have respiratory infections, suggestive of a dysregulated microbiome. Here we demonstrate that end-stage LAM patients have a distinct microbiome signature compared to patients with end-stage chronic obstructive pulmonary disease.
format Online
Article
Text
id pubmed-8549264
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85492642021-10-27 The lung microbiome in end-stage Lymphangioleiomyomatosis Ng, Julie Pacheco-Rodriguez, Gustavo Begley, Lesa Huang, Yvonne J. Poli, Sergio Perrella, Mark A. Rosas, Ivan O. Moss, Joel El-Chemaly, Souheil Respir Res Letter to the Editor Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease with mortality driven primarily by respiratory failure. Patients with LAM frequently have respiratory infections, suggestive of a dysregulated microbiome. Here we demonstrate that end-stage LAM patients have a distinct microbiome signature compared to patients with end-stage chronic obstructive pulmonary disease. BioMed Central 2021-10-26 2021 /pmc/articles/PMC8549264/ /pubmed/34702264 http://dx.doi.org/10.1186/s12931-021-01873-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Letter to the Editor
Ng, Julie
Pacheco-Rodriguez, Gustavo
Begley, Lesa
Huang, Yvonne J.
Poli, Sergio
Perrella, Mark A.
Rosas, Ivan O.
Moss, Joel
El-Chemaly, Souheil
The lung microbiome in end-stage Lymphangioleiomyomatosis
title The lung microbiome in end-stage Lymphangioleiomyomatosis
title_full The lung microbiome in end-stage Lymphangioleiomyomatosis
title_fullStr The lung microbiome in end-stage Lymphangioleiomyomatosis
title_full_unstemmed The lung microbiome in end-stage Lymphangioleiomyomatosis
title_short The lung microbiome in end-stage Lymphangioleiomyomatosis
title_sort lung microbiome in end-stage lymphangioleiomyomatosis
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549264/
https://www.ncbi.nlm.nih.gov/pubmed/34702264
http://dx.doi.org/10.1186/s12931-021-01873-y
work_keys_str_mv AT ngjulie thelungmicrobiomeinendstagelymphangioleiomyomatosis
AT pachecorodriguezgustavo thelungmicrobiomeinendstagelymphangioleiomyomatosis
AT begleylesa thelungmicrobiomeinendstagelymphangioleiomyomatosis
AT huangyvonnej thelungmicrobiomeinendstagelymphangioleiomyomatosis
AT polisergio thelungmicrobiomeinendstagelymphangioleiomyomatosis
AT perrellamarka thelungmicrobiomeinendstagelymphangioleiomyomatosis
AT rosasivano thelungmicrobiomeinendstagelymphangioleiomyomatosis
AT mossjoel thelungmicrobiomeinendstagelymphangioleiomyomatosis
AT elchemalysouheil thelungmicrobiomeinendstagelymphangioleiomyomatosis
AT ngjulie lungmicrobiomeinendstagelymphangioleiomyomatosis
AT pachecorodriguezgustavo lungmicrobiomeinendstagelymphangioleiomyomatosis
AT begleylesa lungmicrobiomeinendstagelymphangioleiomyomatosis
AT huangyvonnej lungmicrobiomeinendstagelymphangioleiomyomatosis
AT polisergio lungmicrobiomeinendstagelymphangioleiomyomatosis
AT perrellamarka lungmicrobiomeinendstagelymphangioleiomyomatosis
AT rosasivano lungmicrobiomeinendstagelymphangioleiomyomatosis
AT mossjoel lungmicrobiomeinendstagelymphangioleiomyomatosis
AT elchemalysouheil lungmicrobiomeinendstagelymphangioleiomyomatosis

Ejemplares similares